Full Product Details
Author: Ala F. Nassar
Publisher: John Wiley & Sons Inc
Imprint: John Wiley & Sons Inc
Dimensions:
Width: 16.30cm
, Height: 2.40cm
, Length: 24.10cm
Weight: 0.644kg
ISBN: 9780470504789
ISBN 10: 0470504781
Pages: 344
Publication Date: 12 November 2010
Audience:
Professional and scholarly
,
College/higher education
,
Professional & Vocational
,
Postgraduate, Research & Scholarly
Format: Hardback
Publisher's Status: Active
Availability: Out of stock
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.
Reviews
The goal of this book is to improve the readers' knowledge of metabolite elucidation in drug metabolism by exposing them to in depth coverage of the biotransformation of xenobiotics, strategies for identifying and characterizing metabolites, FDA guidelines, and case studies on how to improve the decision-making process in structural modification of drug candidates to reduce toxicity. (Yahoo! Finance US, 26 January 2011)
Contributors mostly from pharmaceutical companies provide a systematic introduction to characterizing metabolites, which has become an important element in drug discovery. They write for scientists involved in designing, developing, and advancing metabolic characterizations for drug discovery and development, and for researchers and students in fields that might call for such characterizations. ( Book News Inc., February 2011)
Contributors mostly from pharmaceutical companies provide a systematic introduction to characterizing metabolites, which has become an important element in drug discovery. They write for scientists involved in designing, developing, and advancing metabolic characterizations for drug discovery and development, and for researchers and students in fields that might call for such characterizations. (Book News Inc., February 2011)
Author Information
ALA F. NASSAR, PHD, has worked in the pharmaceutical industry for more than ten years. For over five years, Dr. Nassar oversaw the drug metabolism and bioanalytical department at Vion Pharmaceuticals, working in these key areas of drug discovery and development. One principal area of his research involved understanding how structure modification can improve the ADME profile for new chemical entities as they advance toward clinical candidacy. He identified and subsequently patented pharmacologically active metabolites of Nexavar (sorafenib), and recently identified the pharmacologically active metabolite of Onrigin (laromustine), and is in the process of seeking a patent on this discovery. Dr. Nassar has more than fifty publications in journal articles and book chapters; and has taught and coordinated several courses on bioanalytical chemistry, LC-MS, and drug metabolism to share his experience with other scientists in the field. Currently, he is the Director of the Mass Spectrometry Facility and Research Assistant Professor at Brandeis University.
